The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype
- PMID: 17971818
- DOI: 10.1038/sj.clpt.6100406
The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype
Abstract
Inferring CYP2D6 phenotype from genotype is increasingly challenging, considering the growing number of alleles and their range of activity. This complexity poses a challenge in translational research where genotyping is being considered as a tool to personalize drug therapy. To simplify genotype interpretation and improve phenotype prediction, we evaluated the utility of an "activity score" (AS) system. Over 25 CYP2D6 allelic variants were genotyped in 672 subjects of primarily Caucasian and African-American heritage. The ability of genotype and AS to accurately predict phenotype using the CYP2D6 probe substrate dextromethorphan was evaluated using linear regression and clustering methods. Phenotype prediction, given as a probability for each AS group, was most accurate if ethnicity was considered; among subjects with genotypes containing a CYP2D6*2 allele, CYP2D6 activity was significantly slower in African Americans compared to Caucasians. The AS tool warrants further prospective evaluation for CYP2D6 substrates and in additional ethnic populations.
Comment in
-
CYP2D6 phenotype prediction from genotype: which system is the best?Clin Pharmacol Ther. 2008 Feb;83(2):225-7. doi: 10.1038/sj.clpt.6100455. Clin Pharmacol Ther. 2008. PMID: 18202689
Similar articles
-
CYP2D6 phenotype prediction from genotype: which system is the best?Clin Pharmacol Ther. 2008 Feb;83(2):225-7. doi: 10.1038/sj.clpt.6100455. Clin Pharmacol Ther. 2008. PMID: 18202689
-
Comparison of three CYP2D6 probe substrates and genotype in Ghanaians, Chinese and Caucasians.Pharmacogenetics. 1998 Aug;8(4):325-33. doi: 10.1097/00008571-199808000-00006. Pharmacogenetics. 1998. PMID: 9731719
-
Unique CYP2D6 activity distribution and genotype-phenotype discordance in black Americans.Clin Pharmacol Ther. 2002 Jul;72(1):76-89. doi: 10.1067/mcp.2002.125783. Clin Pharmacol Ther. 2002. PMID: 12152006 Clinical Trial.
-
CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants.Pharmacogenomics. 2002 Mar;3(2):229-43. doi: 10.1517/14622416.3.2.229. Pharmacogenomics. 2002. PMID: 11972444 Review.
-
Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I.Clin Pharmacokinet. 2009;48(11):689-723. doi: 10.2165/11318030-000000000-00000. Clin Pharmacokinet. 2009. PMID: 19817501 Review.
Cited by
-
Clinical effects of CYP2D6 phenoconversion in patients with psychosis.J Psychopharmacol. 2024 Dec;38(12):1095-1110. doi: 10.1177/02698811241278844. Epub 2024 Sep 23. J Psychopharmacol. 2024. PMID: 39310932 Free PMC article.
-
Mechanisms of resistance to endocrine therapy in breast cancer: focus on signaling pathways, miRNAs and genetically based resistance.Int J Mol Sci. 2012 Dec 20;14(1):108-45. doi: 10.3390/ijms14010108. Int J Mol Sci. 2012. PMID: 23344024 Free PMC article. Review.
-
High frequency of CYP2D6 ultrarapid metabolizer genotypes in an Ashkenazi Jewish population from Argentina.Pharmacogenomics J. 2017 Jul;17(4):378-381. doi: 10.1038/tpj.2016.27. Epub 2016 Apr 12. Pharmacogenomics J. 2017. PMID: 27068265
-
Cypiripi: exact genotyping of CYP2D6 using high-throughput sequencing data.Bioinformatics. 2015 Jun 15;31(12):i27-34. doi: 10.1093/bioinformatics/btv232. Bioinformatics. 2015. PMID: 26072492 Free PMC article.
-
Tamoxifen side effects: pharmacogenetic and clinical approach in Mexican mestizos.Transl Cancer Res. 2019 Feb;8(1):23-34. doi: 10.21037/tcr.2018.12.27. Transl Cancer Res. 2019. PMID: 35116730 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials